Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients

The objective of the present study was to determine if there is a health-related quality of life (HRQL) instrument, generic or specific, that better represents functional capacity dysfunction in idiopathic pulmonary fibrosis (IPF) patients. HRQL was evaluated in 20 IPF patients using generic and specific questionnaires (Medical Outcomes Short Form 36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ), respectively). Functional status was evaluated by pulmonary function tests, 6-min walking distance test (6MWDT) and dyspnea indexes (baseline dyspnea index) at rest and after exercise (modified Borg scale). There was a restrictive pattern with impairment of diffusion capacity (total lung capacity, TLC = 71.5 ± 15.6%, forced vital capacity = 70.4 ± 19.4%, and carbon monoxide diffusing capacity = 41.5 ± 16.2% of predicted value), a reduction in exercise capacity (6MWDT = 435.6 ± 95.5 m) and an increase of perceived dyspnea score at rest and during exercise (6 ± 2.5 and 7.1 ± 1.3, respectively). Both questionnaires presented correlation with some functional parameters (TLC, forced expiratory volume in 1 s and carbon monoxide diffusing capacity) and the best correlation was with TLC. Almost all of the SGRQ domains presented a strong correlation with functional status, while in SF-36 only physical function and vitality presented a good correlation with functional status. Dyspnea index at rest and 6MWDT also presented a good correlation with HRQL. Our results suggest that a specific instead of a generic questionnaire is a more appropriate instrument for HRQL evaluation in IPF patients and that TLC is the functional parameter showing best correlation with HRQL

Incorporating Descriptive Metadata into Seismic Source Zone Models for Seismic Hazard Assessment: A case study of the Azores-West Iberian region

In probabilistic seismic-hazard analysis (PSHA), seismic source zone (SSZ) models are widely used to account for the contribution to the hazard from earth- quakes not directly correlated with geological structures. Notwithstanding the impact of SSZ models in PSHA, the theoretical framework underlying SSZ models and the criteria used to delineate the SSZs are seldom explicitly stated and suitably docu- mented. In this paper, we propose a methodological framework to develop and docu- ment SSZ models, which includes (1) an assessment of the appropriate scale and degree of stationarity, (2) an assessment of seismicity catalog completeness-related issues, and (3) an evaluation and credibility ranking of physical criteria used to delin- eate the boundaries of the SSZs. We also emphasize the need for SSZ models to be supported by a comprehensive set of metadata documenting both the unique character- istics of each SSZ and the criteria used to delineate its boundaries. This procedure ensures that the uncertainties in the model can be properly addressed in the PSHA and that the model can be easily updated whenever new data are available. The pro- posed methodology is illustrated using the SSZ model developed for the Azores–West Iberian region in the context of the Seismic Hazard Harmonization in Europe project (project SHARE) and some of the most relevant SSZs are discussed in detail

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types